HemoSonics Celebrates NIH Grant for Maternal Health Innovation
In a significant achievement, HemoSonics, LLC, a company dedicated to advancing medical technologies for acute bleeding management, has received one of the prestigious awards from the National Institutes of Health (NIH) as part of the RADx Tech for Maternal Health Challenge. This initiative aims to catalyze innovative solutions that effectively address the shocking rates of maternal mortality worldwide.
Understanding the Maternal Mortality Crisis
Severe bleeding after childbirth, known as postpartum hemorrhage (PPH), stands as the leading cause of maternal mortality globally, claiming approximately 70,000 lives each year according to the World Health Organization. Annually, around 14 million women face this serious risk. Notably, the U.S. reports a maternal mortality rate that highlights the acuteness of this issue, with a staggering 21.1 deaths per 100,000 live births, which is nearly double the average reported by the Organization for Economic Cooperation and Development.
The Impact of Postpartum Hemorrhage
Despite advancements in healthcare, postpartum hemorrhage continues to pose a grave risk to new mothers. The alarming statistic indicates that 10% of maternal deaths globally are attributed to bleeding complications. This emphasizes the urgent need for innovative diagnostic tools and better management strategies in obstetrics.
Details of the NIH Award
HemoSonics was recognized for its pioneering research with the Quantra Hemostasis System, which has shown promising results in managing peripartum bleeding in obstetric patients. Out of more than 80 submissions in the RADx Tech for Maternal Health Challenge, HemoSonics emerged as one of the eight grant recipients, receiving a $525,000 prize aimed at further developing their diagnostic approach.
Key Features of the Quantra System
The Quantra Hemostasis System, which is already FDA-cleared for several surgical applications, utilizes advanced technology to offer precise evaluation of blood coagulation. By enabling standardized, operationally efficient testing, it assists clinicians in making informed decisions regarding bleeding management. The system's innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance) measures the coagulation properties of blood, providing rapid results typically in under 15 minutes.
The Role of the IMPROVE Initiative
The NIH's initiative that includes the RADx Tech for Maternal Health Challenge, known as IMPROVE, focuses on reducing preventable maternal deaths and addressing health disparities among affected populations. Launched in response to the alarming rate of pregnancy-related complications, the program scrutinizes leading causes of maternal morbidity and mortality alongside special considerations for marginalized groups.
Commitment to Women's Health
With this award, HemoSonics is poised to expand its efforts to enhance maternal healthcare. Bob Roda, President and CEO of HemoSonics, expressed profound appreciation for the recognition from the NIH. He affirmed the company's commitment to developing technologies that ensure safe childbirth experiences for women across varying circumstances.
About HemoSonics
Based in Durham, North Carolina, HemoSonics is part of the Stago Group, global leaders in diagnostics focused on thrombosis and hemostasis. The organization's flagship product, the Quantra Hemostasis Analyzer, aims to redefine bleeding management through rapid and precise diagnostic outcomes, contributing to better patient care and reduced healthcare costs.
Frequently Asked Questions
What is the significance of the NIH grant for HemoSonics?
The NIH grant allows HemoSonics to further develop the Quantra Hemostasis System, focusing on improving outcomes for women suffering from postpartum hemorrhage.
How does the Quantra Hemostasis System work?
The system uses advanced ultrasound technology to measure blood coagulation properties, providing fast results to assist clinicians in managing bleeding effectively.
Why is postpartum hemorrhage a critical health issue?
Postpartum hemorrhage is the leading cause of maternal deaths globally, affecting millions of women each year and illustrating the need for innovative solutions in obstetric care.
What are the aims of the IMPROVE initiative?
The IMPROVE initiative aims to reduce maternal mortality rates by addressing preventable causes of maternal deaths and improving care across different populations.
What role does HemoSonics play in maternal health?
HemoSonics focuses on developing diagnostic solutions to enhance bleeding management, ultimately aiming to improve health outcomes for women during and after childbirth.
